For the treatment of PAH, endothelin receptor antagonists, prostacyclin analogues, a prostaglandin I2 receptor agonist, phosphodiesterase type 5 inhibitors, and a soluble guanylate cyclase stimulator have been approved (1). This evidence concerns the gene PTGIR and pulmonary arterial hypertension.